Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis

doi:10.4252/wjsc.v17.i7.108202

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-6)

Tables (1-3)

Sum=1

Jul 26, 2025 (publication date) through Jul 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Stem Cells. Jul 26, 2025; 17(7): 108202
Published online Jul 26, 2025. doi: 10.4252/wjsc.v17.i7.108202

Open in New Tab Full Size Figure Download Figure

Figure 1 Preferred Reporting Items for Systematic Reviews - a flow chart of the study selection process for the effects of mesenchymal stem cell-based therapies for diabetes mellitus.

Open in New Tab Full Size Figure Download Figure

Figure 2 The forest plots resulted from the meta-analysis of the effect of bone marrow-derived mesenchymal stem cell-based therapies on various glycemic outcomes. A: Hemoglobin A1c; B: Fasting blood glucose; C: C-peptide level; D: Insulin requirements. CI: Confidence interval.

Open in New Tab Full Size Figure Download Figure

Figure 3 The forest plots resulted from the meta-analysis of the effect of allogeneic and autologous transplanted mesenchymal stem cell-based therapies on various glycemic outcomes. A: Hemoglobin A1c; B: Fasting blood glucose; C: C-peptide level; D: Insulin requirements. CI: Confidence interval; HbA1c: Hemoglobin A1c.

Open in New Tab Full Size Figure Download Figure

Figure 4 The results of assessment of risk of bias in the studies that underwent meta-analysis.

Open in New Tab Full Size Figure Download Figure

Figure 5 The safety assessment of mesenchymal stem cell-based therapies in patients suffering from diabetes mellitus.

Open in New Tab Full Size Figure Download Figure

Figure 6 Various non-glycemic effects of mesenchymal stem cell-based therapies on patients with diabetes mellitus. MSC: Mesenchymal stem cell.

Citation: Aringazina RA, Zare A, Mousavi SM, Abenova N, Mussin NM, Tamadon A. Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis. World J Stem Cells 2025; 17(7): 108202
URL: https://www.wjgnet.com/1948-0210/full/v17/i7/108202.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i7.108202